Geode Capital Management
IMNP

Geode Capital Management’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Geode Capital Management’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-22,355
Closed -$4K – 4185
2018
Q2 		$4K Hold
22,355
– – ﹤0.01% 4064
2018
Q1 		$7K Hold
22,355
– – ﹤0.01% 4041
2017
Q4 		$12K Hold
22,355
– – ﹤0.01% 4007
2017
Q3 		$33K Hold
22,355
– – ﹤0.01% 3980
2017
Q2 		$69K Sell
22,355
-22,352
-50% -$60K ﹤0.01% 3899
2017
Q1 		$130K Buy
44,707
+22,354
+100% +$80.7K ﹤0.01% 3772
2016
Q4 		$81K Buy
22,353
+10,217
+84% +$42K ﹤0.01% 3828
2016
Q3 		$67K Buy
12,136
+7,140
+143% +$52.7K ﹤0.01% 3886
2016
Q2 		$39K Hold
4,996
– – ﹤0.01% 3966
2016
Q1 		$42 Hold
4,996
– – ﹤0.01% 3994
2015
Q4 		$73K Hold
4,996
– – ﹤0.01% 3947
2015
Q3 		$117K Buy
+4,996
New +$157K ﹤0.01% 3856

Other funds holding IMNP

IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Geode Capital Management's IMNP Position: Q3 2018 in Review

Geode Capital Management sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2018, closing a stake of 22,355 shares — an estimated $4K sold.

Geode Capital Management first reported a position in IMNP in Q3 2015 and held it in 12 quarters. The position peaked at $130K in Q1 2017. 1 fund tracked by Wall St. Rank holds IMNP as of Q3 2018.

  • Geode Capital Management reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Geode Capital Management sold 22,355 Immune Pharmaceuticals Inc. shares in Q3 2018, an estimated $4K.
  • Geode Capital Management first reported a position in Immune Pharmaceuticals Inc. in Q3 2015 and held it in 12 quarters.
  • Geode Capital Management's Immune Pharmaceuticals Inc. position peaked at $130K in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2018.

Based on Geode Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.